Three leading scientific congresses. One integrated platform. Bringing together the future of advanced therapeutics manufacturing in Asia.
Attendees
Companies
Speakers
About The Events
In 2026, Cell & Gene Therapy World Asia 2026, RNA Therapeutics & Manufacturing Asia 2026, and Oligonucleotides & Peptides World Asia Congress 2026 will be co-located in Singapore, creating a unified platform for the most advanced therapeutic modalities shaping the future of biopharma.
Over two intensive days, the event will unite cell & gene therapy, RNA therapeutics, and oligonucleotide & peptide development under one roof—enabling cross-disciplinary learning, collaboration, and partnership across the entire value chain.
This co-located format is designed to break silos, encourage shared innovation, and accelerate the translation of science into scalable, commercial therapies.
Key Themes & Topics
Advanced Therapeutic Modalities
This theme explores the rapid evolution of cell & gene therapies, RNA therapeutics, and oligonucleotide & peptide medicines, highlighting how these advanced modalities are reshaping treatment paradigms. Sessions will focus on emerging platforms, modality convergence, and translational strategies that bridge discovery science with clinical and commercial outcomes.
Manufacturing Innovation & Scale-Up
As advanced therapies move closer to commercialisation, manufacturing scalability and robustness become critical. This theme will examine process development, scale-up strategies, automation, and digital manufacturing solutions designed to improve efficiency, reduce costs, and ensure consistent product quality across complex therapeutic modalities.
Analytics, Quality & CMC Strategy
Robust analytics and CMC strategies are essential for regulatory success and long-term product lifecycle management. Discussions will cover analytical method development, quality control, stability testing, comparability, and GMP readiness, supporting seamless transitions from early development to commercial manufacturing.
Formulation & Delivery Technologies
Effective delivery remains one of the biggest challenges in advanced therapeutics. This theme will highlight viral and non-viral delivery systems, lipid nanoparticles, conjugation technologies, and formulation strategies aimed at enhancing stability, targeting, and therapeutic performance across diverse drug modalities.
Regulatory Pathways & Market Access
Navigating regulatory landscapes across Asia-Pacific requires both regional insight and global alignment. Sessions under this theme will address regulatory expectations, approval pathways, and compliance strategies, alongside considerations for clinical development, commercial launch, and market access.
Partnerships, CDMOs & Ecosystem Growth
Collaboration is key to accelerating innovation and reducing development risk. This theme focuses on strategic partnerships, CDMO engagement, outsourcing models, and supply chain resilience, highlighting how cross-industry collaboration strengthens the advanced therapeutics ecosystem in Asia.
Future Trends & Sustainability
Looking ahead, this theme explores emerging trends shaping the future of advanced therapeutics, including digitalisation, AI-enabled manufacturing, sustainability initiatives, workforce development, and investment strategies that will define the next phase of biopharmaceutical growth.
Why Attend
One Location. Three Communities. Endless Opportunities.
- Access insights from global industry leaders and technical experts
- Learn best practices across R&D, clinical development, manufacturing, and quality
- Discover how Asia is emerging as a global hub for advanced therapeutics
- Network with biotech, pharma, CDMOs, regulators, and technology providers
- Move seamlessly between conferences and sessions with one pass
Who Should Attend
- Biotech & pharmaceutical executives
- Cell, gene, RNA, and oligo/peptide scientists
- Manufacturing, process development & quality leaders
- Clinical development & CMC professionals
- CDMOs & technology solution providers
- Regulators & policy stakeholders
